Stock Screener App

Frei -

Installieren

0.5015

7.30% -0.0395

Skye Bioscience Inc (SKYE)

Überblick Nachrichten Preisverlauf Forum Prognose

Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten

Skye drops obesity program, combines with Redx to form Fibrx - AllSci

Skye Bioscience Q2 Loss Narrows Sharply on Lower R&D Spending - Minichart

SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease - TradingView

Skye Bioscience to Be Acquired by Redx Pharma in $264.5M Nasdaq-Listed Merger - Minichart

SKYE: Merger creates a well-funded fibrosis company advancing RXC008 for Crohn's disease, with phase II data due 2029 - TradingView

Form 8K Skye Bioscience Inc For: 14 August By Investing.com - Investing.com India

Skye Bioscience to acquire Redx Pharma in $125M deal By Investing.com - Investing.com UK

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line - TradingView

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary - TradingView

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding - stocktitan.net

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings - marketscreener.com

Skye Bioscience Inc (SKYE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Skye Bioscience Inc (SKYE) Stock News Today - TradingKey

SKYE Q2'26 Earnings: EPS estimate is (0.24) USD - TradingView

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks

Skye Bioscience2026 Funding Rounds & List of Investors - Tracxn

SKYE Q2'26 Earnings: revenue estimate is 0 USD - TradingView

Skye Bioscience Inc (SKYE) Cash Flow - TradingKey

Skye Bioscience Inc (SKYE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

SKYE|Skye Bioscience Inc|Price:0.625|Chg%:-0.027 - TradingKey

Skye Bioscience, Inc. Revenue Breakdown – LSX:A3ES4X - TradingView

Skye Bioscience Inc (SKYE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Skye Bioscience Inc (SKYE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Skye Bioscience Market Sentiment - Benzinga España

TradingKey - TradingKey

Skye Bioscience Inc (SKYE) Institutional Confidence - TradingKey

Skye Bioscience Lawsuit: Company and CEO Move to Dismiss Claims - TipRanks

Skye Bioscience (SKYE) Edges Higher as Stock Holds Above Key Support at $0.63Wide Range Bar - dars.gov.et

Skye Bioscience (SKYE) Slides Toward Support as Bearish Pressure PersistsJelly Roll Trade - dars.gov.et

SKYE Technical Analysis | Trend, Signals & Chart Patterns - ChartMill

Skye Bioscience (SKYE) Nudges Higher as Biotech Sector Finds FootingVWAP Deviation - dars.gov.et

SKYE Q1 2026 Earnings: Clinical-Stage Biotech Reports EPS Miss Amid Ongoing Pipeline Development - dars.gov.et

Skye Bioscience Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Pipeline DevelopmentQuarterly Earnings - dars.gov.et

SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Acceleration Picks - dars.gov.et

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz - The National Law Review

Bronstein, Gewirtz & Grossman, LLC Encourages Skye Bioscience, In - The National Law Review

Skye Bioscience, Inc. Financial Disclosures & SEC Filings - TradingView

Price to earnings forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Enterprise value to revenue forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Price to book forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Enterprise value to EBIT forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Price to sales forward of Skye Bioscience, Inc. – NASDAQ:SKYE - TradingView

Skye Bioscience, Inc. Actuals & Estimates (NASDAQ:SKYE) - TradingView

Skye Bioscience, Inc. Actuals & Estimates (FWB:09R) - TradingView

SKYE Forecast — Price Target — Prediction for 2027 - TradingView

Skye Bioscience Moves Listing to Nasdaq Capital Market - The Globe and Mail

Skye Bioscience to Move Listing to Nasdaq Capital Market After Equity Shortfall - TradingView

Skye Bioscience (NASDAQ: SKYE) shifts to Nasdaq Capital Market amid listing notices - Stock Titan

Skye Bioscience Inc (SKYE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Skye Bioscience, Inc. Stock 12‑Month Price Target Cut to $7.33, Implies 937% Upside - TradingView

Skye Bioscience Inc (SKYE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Skye Bioscience Inc (SKYE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Skye Bioscience Inc (SKYE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Skye Bioscience (SKYE) Edges Higher as Shares Hold Above Key SupportGEX Level - dars.gov.et

Piper Sandler Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Cuts Target Price to $6 - 富途牛牛

SKYE News | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill

SKYE Q1 2026 Earnings: Narrow EPS Miss Amid Active Clinical Pipeline ProgressRevenue Breakdown Analysis - DonanımHaber

Skye Bioscience (SKYE) Surges 5% as Key Support Holds, Resistance in FocusPut Wall - newsline.com

SKYE Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline, Stock RisesEBITDA Margin Trends - newsline.com

MRNA

$63.32

0.52%

RPRX

$58.60

0.07%

ROIV

$36.20

0.22%

INSM

$123.74

2.05%

ALNY

$228.65

0.67%

ONC

$347.48

2.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters